Tag Archive for: oncology

Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline

/in

Strengthening of strategic option license agreement to cover additional novel ADC targets Copenhagen, Denmark, May 30th, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, announced the expansion of its current collaboration with Duality Biologics (“Duality”), a clinical-stage […]

Read more

InProTher announces EUR 6MSeed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy

/in

• Danish start-up developing immunotherapies designed to fight the tumors from within • Financing supports GMP and tox studies and will advance InProTher’s first-in-class cancer immunotherapy into First-in-Human clinical trials • Strengthens team with appointment of industry heavyweights Dr. Sven Rohman as Chairman and Dr. Hamina Patel as CMO Copenhagen, Denmark, 24 May 2023: InProTher, an early-stage biotechnologycompany developing effective immunotherapies targeting the Human Endogenous Retroviruses (HERVs), today announces that it has raised EUR 6M of Seed funding from private investors with the participation of the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug […]

Read more

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors

/in

Leading industry expert with more than 25 years of experience in translation research in immunology  Basel, Switzerland, 23 May 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D’Andrea to its board of directors as a non-executive director as of […]

Read more

Peer-Reviewed Translational Research Paves The Way For First-In-Class Autotaxin Inhibitor IOA-289 In Cancer

/in

Amsterdam, The Netherlands and Geneva, Switzerland, 16 May 2023 – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the peer-reviewed publication of comprehensive translational research on the novel autotaxin (ATX) inhibitor IOA-289 in the ESMO journal Immuno-Oncology and Technology (IOTECH). Read more…

Read more

iOnctura Expands Pipeline And Receives Development Grant From Health Holland And KWF

/in

Licensing deal gives iOnctura exclusive global development rights to novel TGFβ pathway inhibitor IOA-359 Pipeline expansion builds on iOnctura’s strategy of targeting multiple cancer survival pathways with a single drug; in this case targeting therapy resistance and immune evasion pathways in addition to IOA-359’s direct effects on the tumor Grant will accelerate iOnctura’s preclinical investigation of […]

Read more